TRIVARIS
LOE ApproachingNDAINTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREALINJECTABLE
Approved
Jun 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 10h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRIVARIS is a small-molecule injectable approved in 2008 by AbbVie, administered via intra-articular, intramuscular, or intravitreal routes. The product indication(s) remain undisclosed in available data, but the multi-route formulation suggests musculoskeletal or ophthalmologic applications. Mechanism of action is not publicly specified.
LOE Approaching
Product is in lifecycle decline with limited spending data, suggesting reduced team headcount and commercial focus shifting toward LOE mitigation strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's declining commercial phase; career opportunities on TRIVARIS are limited and defensive in nature. Professionals assigned to this brand should expect roles focused on market maintenance, competitive response, or transition planning rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on TRIVARIS at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.